KRAS and cancer: 5) without detectable ctDNA at relapse carried a KRAS hot spot mutation found at subclonal levels in the primary tumor tissue, pointing to the presence of intra-tumoral heterogeneity and clonal selection during cancer progression (Khan et al., 2018).